Author details
Author Olivier Lohest |
Available item(s) by this author (4)
Add the result to your basket Make a suggestion Refine your search Apply to external sources
Het referentieprijssysteem en socio-economische verschillen bij het gebruik van goedkopere geneesmiddelen / France Vrijens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
Het referentieprijssysteem en socio-economische verschillen bij het gebruik van goedkopere geneesmiddelen [printed text] / France Vrijens , Author ; Carine Van de Voorde, Author ; Maria-Isabel Farfan-Portet, Author ; Maïté le Polain, Author ; Olivier Lohest, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2010 . - IX, 69 p. : ill. ; A4. - (KCE Reports A. Health Services Research (HSR); 126A) .
ISSN : D/2010/10.273/18 : 0 €.
Studie nr 2008-08
Languages : Dutch (dut) English (eng)
Descriptors: Classification
QV 736 Drug industry. Economics of pharmacy. Advertising
Indexation
2008-08 ; Cost-sharing ; Drugs, Generic ; Population Characteristics ; Prescriptions, Drug ; R126 ; Reimbursement Mechanisms ; Socioeconomic FactorsAbstract: Het Federaal Kenniscentrum voor de Gezondheidszorg (KCE) ging na of alle Belgen, ongeacht hun socio-economische achtergrond, financieel voordeel halen uit het bestaan van generische geneesmiddelen of bepaalde originele producten waarvan de prijs werd verlaagd. Het resultaat is bemoedigend, want net de minst bevoorrechte Belgen blijken iets meer dergelijke producten te kopen. Toch kan het nog beter. Artsen en apothekers kunnen aangespoord worden om goedkopere producten meer voor te schrijven en af te leveren . En ook de patiënt zou meer informatie kunnen krijgen over de meerprijs die hij betaalt bij de aankoop van een geneesmiddel waarvoor er een goedkoper alternatief bestaat. Contents note: Table of contents -- LIST OF ABRREVIATIONS 3 -- GLOSSARY 4 -- 1 INTRODUCTION AND RESEARCH QUESTIONS 7 -- 1.1 BACKGROUND 7 -- 1.2 RESEARCH QUESTIONS AND SCOPE 8 -- 1.3 CONTENT OF THIS REPORT 8 -- 2 INTERNATIONAL COMPARISON OF REFERENCE PRICING 9 -- 2.1 INTRODUCTION 9 -- 2.2 GENERAL DESCRIPTION OF THE REFERENCE PRICE SYSTEM 10 -- 2.2.1 Definition 10 -- 2.2.2 General characteristics of a reference price system 11 -- 2.3 OVERVIEW OF THE REFERENCE PRICE SYSTEM IN A SELECTION OF 11 OECD -- COUNTRIES 13 -- 2.3.1 Methods 13 -- 2.3.2 Definition and scope of the cluster 14 -- 2.3.3 The reference price level 16 -- 2.3.4 Measures for physicians, pharmacists and patients 16 -- 2.4 DESCRIPTION OF THE BELGIAN REFERENCE PRICE SYSTEM 18 -- 2.4.1 Evolution of the legal basis of the RPS 19 -- 2.4.2 Definition and scope of the cluster 21 -- 2.4.3 The reference price level 21 -- 2.4.4 The security margin 23 -- 2.4.5 Exemptions 23 -- 2.4.6 Measures for physicians, pharmacists and patients 23 -- 3 IMPACT OF THE REFERENCE PRICE SYSTEM: A LITERATURE REVIEW 28 -- 3.1 INTRODUCTION 28 -- 3.2 METHODS 28 -- 3.3 RESULTS 29 -- 3.3.1 Search strategy and study selection of the review studies on the impact of a RPS 29 -- 3.3.2 Association of the RPS with drug use 30 -- 3.3.3 Association of the RPS with drug prices 30 -- 3.3.4 Association of the RPS with drug expenditures 30 -- 3.3.5 Association of the RPS with health services use and health 31 -- 4 RESULTS FROM THE ANALYSIS OF BELGIAN PRESCRIPTION DATA IN 2008 32 -- 4.1 INTRODUCTION 32 -- 4.2 THE BELGIAN PHARMACEUTICAL MARKET: EVOLUTION OF MARKET SHARES AND -- OUT-OF-POCKET PAYMENTS 33 -- 4.2.1 Evolution of market shares 33 -- 4.2.2 The reference supplement in 2008 36 -- 4.3 IMPACT OF THE REFERENCE PRICE SYSTEM IN BELGIUM: LITERATURE REVIEW 39 -- 4.3.1 Market share of low cost drugs 39 -- 4.3.2 Expenditures for the NIHDI and for patients 39 -- 4.3.3 Potential gains from the increasing use of low cost drugs 39 -- 4.3.4 Strategies by pharmaceutical firms 40 -- 4.4 METHODS 40 -- 4.4.1 Data sources 40 -- 4.4.2 Time period 41 -- 4.4.3 Selection of data (sampling procedure) 41 -- 4.4.4 Coupling procedure and authorisation from the Privacy Commission 41 -- 4.4.5 Selection and construction of socioeconomic variables 41 -- 4.4.6 Selection of patients and of pharmaceutical products 43 -- 4.4.7 Statistical analyses 45 -- 4.5 RESULTS 46 -- 4.5.1 Selection of prescribers and patients 46 -- 4.5.2 Choice between high price/low cost drugs 46 -- 4.5.3 Socioeconomic characteristics of patients or physicians and therapeutic reference -- pricing: evidence in the literature 57 -- 4.5.4 Choice of a less costly active ingredient within a class 58 -- 4.5.5 Appraisal of results: barriers to low cost drugs 62 -- 5 SUMMARY, CONCLUSION AND DISCUSSION 63 -- 6 BIBLIOGRAPHY 66 Link for e-copy: https://doi.org/10.57598/R126A Format of e-copy: PDF (749 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1904 Copies(0)
Status No copy Le système du prix de référence et les différences socio-économiques dans l’utilisation des médicaments moins onéreux / France Vrijens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
Le système du prix de référence et les différences socio-économiques dans l’utilisation des médicaments moins onéreux [printed text] / France Vrijens , Author ; Carine Van de Voorde, Author ; Maria-Isabel Farfan-Portet, Author ; Maïté le Polain, Author ; Olivier Lohest, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2010 . - X, 69 p. : ill. ; A4. - (KCE Reports B. Health Services Research (HSR); 126B) .
ISSN : D/2010/10.273/19 : 0 €.
Etude nr 2008-08
Languages : English (eng) French (fre)
Descriptors: Classification
QV 736 Drug industry. Economics of pharmacy. Advertising
Indexation
2008-08 ; Cost-sharing ; Drugs, Generic ; Population Characteristics ; Prescriptions, Drug ; R126 ; Reimbursement Mechanisms ; Socioeconomic FactorsAbstract: Le Centre fédéral d’expertise des soins de santé (KCE) a vérifié si tous les Belges, quel que soit leur statut socio-économique, profitent des avantages financiers que procure l’utilisation de médicaments génériques ou de certains médicaments originaux qui ont baissé leur prix. Le résultat de l’étude est encourageant car ce sont justement les Belges les moins favorisés qui s’avèrent utiliser un peu plus de tels médicaments. Il y aurait tout de même encore moyen de faire mieux, en appliquant des mesures qui encouragent les médecins et les pharmaciens à plus prescrire et délivrer des médicaments moins onéreux. Les patients aussi pourraient recevoir plus d’information sur les suppléments qu’ils paient à l’achat de médicaments pour lesquels une alternative meilleur marché existe. Contents note: Table of contents -- LIST OF ABRREVIATIONS 3 -- GLOSSARY 4 -- 1 INTRODUCTION AND RESEARCH QUESTIONS 7 -- 1.1 BACKGROUND 7 -- 1.2 RESEARCH QUESTIONS AND SCOPE 8 -- 1.3 CONTENT OF THIS REPORT 8 -- 2 INTERNATIONAL COMPARISON OF REFERENCE PRICING 9 -- 2.1 INTRODUCTION 9 -- 2.2 GENERAL DESCRIPTION OF THE REFERENCE PRICE SYSTEM 10 -- 2.2.1 Definition 10 -- 2.2.2 General characteristics of a reference price system 11 -- 2.3 OVERVIEW OF THE REFERENCE PRICE SYSTEM IN A SELECTION OF 11 OECD -- COUNTRIES 13 -- 2.3.1 Methods 13 -- 2.3.2 Definition and scope of the cluster 14 -- 2.3.3 The reference price level 16 -- 2.3.4 Measures for physicians, pharmacists and patients 16 -- 2.4 DESCRIPTION OF THE BELGIAN REFERENCE PRICE SYSTEM 18 -- 2.4.1 Evolution of the legal basis of the RPS 19 -- 2.4.2 Definition and scope of the cluster 21 -- 2.4.3 The reference price level 21 -- 2.4.4 The security margin 23 -- 2.4.5 Exemptions 23 -- 2.4.6 Measures for physicians, pharmacists and patients 23 -- 3 IMPACT OF THE REFERENCE PRICE SYSTEM: A LITERATURE REVIEW 28 -- 3.1 INTRODUCTION 28 -- 3.2 METHODS 28 -- 3.3 RESULTS 29 -- 3.3.1 Search strategy and study selection of the review studies on the impact of a RPS 29 -- 3.3.2 Association of the RPS with drug use 30 -- 3.3.3 Association of the RPS with drug prices 30 -- 3.3.4 Association of the RPS with drug expenditures 30 -- 3.3.5 Association of the RPS with health services use and health 31 -- 4 RESULTS FROM THE ANALYSIS OF BELGIAN PRESCRIPTION DATA IN 2008 32 -- 4.1 INTRODUCTION 32 -- 4.2 THE BELGIAN PHARMACEUTICAL MARKET: EVOLUTION OF MARKET SHARES AND -- OUT-OF-POCKET PAYMENTS 33 -- 4.2.1 Evolution of market shares 33 -- 4.2.2 The reference supplement in 2008 36 -- 4.3 IMPACT OF THE REFERENCE PRICE SYSTEM IN BELGIUM: LITERATURE REVIEW 39 -- 4.3.1 Market share of low cost drugs 39 -- 4.3.2 Expenditures for the NIHDI and for patients 39 -- 4.3.3 Potential gains from the increasing use of low cost drugs 39 -- 4.3.4 Strategies by pharmaceutical firms 40 -- 4.4 METHODS 40 -- 4.4.1 Data sources 40 -- 4.4.2 Time period 41 -- 4.4.3 Selection of data (sampling procedure) 41 -- 4.4.4 Coupling procedure and authorisation from the Privacy Commission 41 -- 4.4.5 Selection and construction of socioeconomic variables 41 -- 4.4.6 Selection of patients and of pharmaceutical products 43 -- 4.4.7 Statistical analyses 45 -- 4.5 RESULTS 46 -- 4.5.1 Selection of prescribers and patients 46 -- 4.5.2 Choice between high price/low cost drugs 46 -- 4.5.3 Socioeconomic characteristics of patients or physicians and therapeutic reference -- pricing: evidence in the literature 57 -- 4.5.4 Choice of a less costly active ingredient within a class 58 -- 4.5.5 Appraisal of results: barriers to low cost drugs 62 -- 5 SUMMARY, CONCLUSION AND DISCUSSION 63 -- 6 BIBLIOGRAPHY 66 Link for e-copy: https://doi.org/10.57598/R126B Format of e-copy: PDF (726 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1903 Copies(0)
Status No copy The reference price system and socioeconomic differences in the use of low cost drugs / France Vrijens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
The reference price system and socioeconomic differences in the use of low cost drugs [printed text] / France Vrijens , Author ; Carine Van de Voorde, Author ; Maria-Isabel Farfan-Portet, Author ; Maïté le Polain, Author ; Olivier Lohest, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2010 . - VIII, 69 p. : ill. ; A4. - (KCE Reports. Health Services Research (HSR); 126C) .
ISSN : D/2010/10.273/20 : 0 €.
Study nr 2008-08
Languages : Dutch (dut) English (eng)
Descriptors: Classification
QV 736 Drug industry. Economics of pharmacy. Advertising
Indexation
2008-08 ; Cost-sharing ; Drugs, Generic ; Population Characteristics ; Prescriptions, Drug ; R126 ; Reimbursement Mechanisms ; Socioeconomic FactorsContents note: LIST OF ABRREVIATIONS.3 -- GLOSSARY.4 -- 1 INTRODUCTION AND RESEARCH QUESTIONS.7 -- 1.1 BACKGROUND.7 -- 1.2 RESEARCH QUESTIONS AND SCOPE.8 -- 1.3 CONTENT OF THIS REPORT.8 -- 2 INTERNATIONAL COMPARISON OF REFERENCE PRICING.9 -- 2.1 INTRODUCTION.9 -- 2.2 GENERAL DESCRIPTION OF THE REFERENCE PRICE SYSTEM.10 -- 2.2.1 Definition.10 -- 2.2.2 General characteristics of a reference price system.11 -- 2.3 OVERVIEW OF THE REFERENCE PRICE SYSTEM IN A SELECTION OF 11 OECD -- COUNTRIES.13 -- 2.3.1 Methods.13 -- 2.3.2 Definition and scope of the cluster.14 -- 2.3.3 The reference price level.16 -- 2.3.4 Measures for physicians, pharmacists and patients.16 -- 2.4 DESCRIPTION OF THE BELGIAN REFERENCE PRICE SYSTEM.18 -- 2.4.1 Evolution of the legal basis of the RPS.19 -- 2.4.2 Definition and scope of the cluster.21 -- 2.4.3 The reference price level.21 -- 2.4.4 The security margin.23 -- 2.4.5 Exemptions.23 -- 2.4.6 Measures for physicians, pharmacists and patients.23 -- 3 IMPACT OF THE REFERENCE PRICE SYSTEM: A LITERATURE REVIEW.28 -- 3.1 INTRODUCTION.28 -- 3.2 METHODS.28 -- 3.3 RESULTS.29 -- 3.3.1 Search strategy and study selection of the review studies on the impact of a RPS.29 -- 3.3.2 Association of the RPS with drug use.30 -- 3.3.3 Association of the RPS with drug prices.30 -- 3.3.4 Association of the RPS with drug expenditures.30 -- 3.3.5 Association of the RPS with health services use and health.31 -- 4 RESULTS FROM THE ANALYSIS OF BELGIAN PRESCRIPTION DATA IN 2008 -- . 32 -- 4.1 INTRODUCTION.32 -- 4.2 THE BELGIAN PHARMACEUTICAL MARKET: EVOLUTION OF MARKET SHARES AND -- OUT-OF-POCKET PAYMENTS.33 -- 4.2.1 Evolution of market shares.33 -- 4.2.2 The reference supplement in 2008.36 -- 4.3 IMPACT OF THE REFERENCE PRICE SYSTEM IN BELGIUM: LITERATURE REVIEW.39 -- 4.3.1 Market share of low cost drugs.39 -- 4.3.2 Expenditures for the NIHDI and for patients.39 -- 4.3.3 Potential gains from the increasing use of low cost drugs.39 -- 4.3.4 Strategies by pharmaceutical firms.40 -- 4.4 METHODS.40 -- 4.4.1 Data sources.40 -- 4.4.2 Time period.41 -- 4.4.3 Selection of data (sampling procedure).41 -- 4.4.4 Coupling procedure and authorisation from the Privacy Commission.41 -- 4.4.5 Selection and construction of socioeconomic variables.41 -- 4.4.6 Selection of patients and of pharmaceutical products.43 -- 4.4.7 Statistical analyses.45 -- 4.5 RESULTS.46 -- 4.5.1 Selection of prescribers and patients.46 -- 4.5.2 Choice between high price/low cost drugs.46 -- 4.5.3 Socioeconomic characteristics of patients or physicians and therapeutic reference -- pricing: evidence in the literature.57 -- 4.5.4 Choice of a less costly active ingredient within a class.58 -- 4.5.5 Appraisal of results: barriers to low cost drugs.62 -- 5 SUMMARY, CONCLUSION AND DISCUSSION.63 -- 6 BIBLIOGRAPHY.66 Link for e-copy: https://doi.org/10.57598/R126C Format of e-copy: PDF (721 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1905 Copies(0)
Status No copy The reference price system and socioeconomic differences in the use of low cost drugs / France Vrijens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
The reference price system and socioeconomic differences in the use of low cost drugs : Supplement [printed text] / France Vrijens , Author ; Carine Van de Voorde, Author ; Maria-Isabel Farfan-Portet, Author ; Maïté le Polain, Author ; Olivier Lohest, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2010 . - VIII, 69 p. : ill. ; A4. - (KCE Reports. Health Services Research (HSR); 126S) .
ISSN : D/2010/10.273/21 : 0 €.
Study nr 2008-08
Languages : English (eng)
Descriptors: Classification
QV 736 Drug industry. Economics of pharmacy. Advertising
Indexation
2008-08 ; Cost-sharing ; Drugs, Generic ; Population Characteristics ; Prescriptions, Drug ; R126 ; Reimbursement Mechanisms ; Socioeconomic FactorsContents note: APPENDICES WITH CHAPTER 2.2 -- 1 SOURCES FOR THE INTERNATIONAL REFERENCE PRICING COMPARISON.2 -- 2 COUNTRY OVERVIEW - CRITERIA DEFINING GROUPS OF DRUGS.6 -- Category 1: Countries with a Level 1 RPS.6 -- Category 2: Countries with a Level 2 RPS.6 -- Category 3: Countries with a multilevel RPS.7 -- 3 COUNTRY OVERVIEW - CRITERIA TO DETERMINE THE REFERENCE PRICE.8 -- Category 1: Countries with a Level 1 RPS.8 -- Category 2: Countries with a Level 2 RPS.8 -- Category 3: Countries with a multilevel RPS.9 -- 4 COUNTRY OVERVIEW - MEASURES FOR PHYSICIANS, PHARMACISTS AND PATIENTS 10 -- Category 1: Countries with a Level 1 RPS.10 -- Category 2: Countries with a Level 2 RPS.12 -- Category 3: Countries with a multilevel RPS.13 -- APPENDICES WITH CHAPTER 3.15 -- 5 ASSOCIATION OF THE RPS WITH OUTCOME MEASURES: REVIEW OF INDIVIDUAL -- STUDIES.15 -- Association of the RPS with drug use.15 -- Association of the RPS with drug prices.17 -- Association of the RPS with drug expenditures.18 -- Association of the RPS with health services use and health.20 -- APPENDICES WITH CHAPTER 4.27 -- 6 RESULTS FOR 12 MOLECULES, CHOICE OF A LOW COST OR HIGH COST ORIGINAL 28 -- 7 PATIENTS USING THE “LEAST COSTLY” MOLECULE(S) WITHIN A CLASS OF DRUGS.40 -- 7.1 Percentage of patients.40 -- 7.2 Regression results.43 -- 7.3 Results from contrast statement: unemployed versus employed.47 -- REFERENCES.48 Link for e-copy: https://doi.org/10.57598/R126S Format of e-copy: PDF (525 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1906 Copies(0)
Status No copy